Biogen Inc. (LON:0R1B)

Market Cap	20.57B +20.6%
Revenue (ttm)	7.35B +2.2%
Net Income	960.62M -20.8%
EPS	6.53 -21.4%
Shares Out	n/a
PE Ratio	21.41
Forward PE	12.18
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,061
Average Volume	987
Open	191.20
Previous Close	190.55
Day's Range	187.39 - 195.97
52-Week Range	110.20 - 203.03
Beta	0.16
RSI	62.19
Earnings Date	Feb 6, 2026

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1978
• Employees: 7,500
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0R1B

Financial Performance

In 2025, Biogen's revenue was $9.89 billion, an increase of 2.22% compared to the previous year's $9.68 billion. Earnings were $1.29 billion, a decrease of -20.79%.

Financial numbers in USD